The newest buying and selling session noticed UnitedHealth Group (UNH) ending at $461.52, denoting a -1.05% adjustment from its final day’s shut. The inventory fell in need of the S&P 500, which registered a lack of 0.5% for the day. Elsewhere, the Dow noticed an upswing of 0.08%, whereas the tech-heavy Nasdaq depreciated by 1.21%.
Shares of the biggest U.S. well being insurer witnessed a lack of 12.41% over the earlier month, trailing the efficiency of the Medical sector with its achieve of two.66% and the S&P 500’s lack of 0.47%.
Market individuals will likely be carefully following the monetary outcomes of UnitedHealth Group in its upcoming launch. The corporate’s upcoming EPS is projected at $7.24, signifying a 4.78% enhance in comparison with the identical quarter of the earlier yr. On the similar time, our most up-to-date consensus estimate is projecting a income of $110.97 billion, reflecting a 11.2% rise from the equal quarter final yr.
For all the fiscal yr, the Zacks Consensus Estimates are projecting earnings of $29.54 per share and a income of $451.19 billion, representing modifications of +6.8% and +12.72%, respectively, from the prior yr.
Buyers also needs to notice any latest modifications to analyst estimates for UnitedHealth Group. These newest changes usually mirror the shifting dynamics of short-term enterprise patterns. With this in thoughts, we are able to take into account optimistic estimate revisions an indication of optimism concerning the firm’s enterprise outlook.
Analysis signifies that these estimate revisions are straight correlated with near-term share value momentum. To capitalize on this, we have crafted the Zacks Rank, a singular mannequin that includes these estimate modifications and provides a sensible ranking system.
Starting from #1 (Robust Purchase) to #5 (Robust Promote), the Zacks Rank system has a confirmed, outside-audited observe document of outperformance, with #1 shares returning a mean of +25% yearly since 1988. Over the previous month, there’s been a 0.65% fall within the Zacks Consensus EPS estimate. At present, UnitedHealth Group is carrying a Zacks Rank of #3 (Maintain).
With respect to valuation, UnitedHealth Group is at the moment being traded at a Ahead P/E ratio of 15.79. This represents a premium in comparison with its trade’s common Ahead P/E of 15.5.
One ought to additional notice that UNH at the moment holds a PEG ratio of 1.27. This well-liked metric is much like the widely-known P/E ratio, with the distinction being that the PEG ratio additionally takes under consideration the corporate’s anticipated earnings development price. Because the market closed yesterday, the Medical – HMOs trade was having a mean PEG ratio of 1.
The Medical – HMOs trade is a part of the Medical sector. At present, this trade holds a Zacks Trade Rank of 203, positioning it within the backside 20% of all 250+ industries.
The power of our particular person trade teams is measured by the Zacks Trade Rank, which is calculated primarily based on the common Zacks Rank of the person shares inside these teams. Our analysis exhibits that the highest 50% rated industries outperform the underside half by an element of two to 1.
Be sure to make the most of Zacks.com to comply with all of those stock-moving metrics, and extra, within the coming buying and selling periods.
Simply Launched: Zacks High 10 Shares for 2025
Hurry – you may nonetheless get in early on our 10 high tickers for 2025. Handpicked by Zacks Director of Analysis Sheraz Mian, this portfolio has been stunningly and persistently profitable. From inception in 2012 via November, 2024, the Zacks High 10 Shares gained +2,112.6%, greater than QUADRUPLING the S&P 500’s +475.6%. Sheraz has combed via 4,400 corporations coated by the Zacks Rank and handpicked the most effective 10 to purchase and maintain in 2025. You possibly can nonetheless be among the many first to see these just-released shares with monumental potential.
UnitedHealth Group Integrated (UNH) : Free Inventory Evaluation Report
This text initially revealed on Zacks Funding Analysis (zacks.com).
The views and opinions expressed herein are the views and opinions of the creator and don’t essentially replicate these of Nasdaq, Inc.
